This article investigates how combining the anti-parasitic medication mebendazole with low-substituted hydroxypropylcellulose into redispersible microparticles significantly improves the drug’s performance.
Because mebendazole is extremely insoluble in water and poorly absorbed by the body, standard treatments require dangerously high doses that frequently cause severe toxic side effects. To address this limitation, the authors used freeze-drying to convert the drug into an amorphous state with enhanced wettability and rapid dissolution. Consequently, oral administration of these innovative microparticles yielded substantially higher bioavailability and maximum plasma concentration than pure mebendazole. Furthermore, testing in a murine model infected with the parasite Trichinella spiralis showed dramatically greater therapeutic efficacy, enabling successful parasite reduction at much lower, safer doses.
Mebendazole (MBZ) is a highly lipophilic, poorly water-soluble benzimidazole derivative categorized as a Biopharmaceutics Classification System (BCS) Class II/IV drug. Because of its low aqueous solubility and extensive hepatic first-pass metabolism, a primary objective in oncology drug repurposing is to enhance its systemic bioavailability. This article discusses in vitro and in vivo preclinical testing (lab & animal).
1. Baseline Pharmacokinetic Bottlenecks
Low Bioavailability & First-Pass Metabolism: Standard oral administration yields a baseline systemic bioavailability of only 17–20% in humans (and drops as low as 1–10% at higher single doses). Ingested mebendazole undergoes rapid, extensive hepatic first-pass degradation, including keto-reduction, decarbamylation, and cytochrome P450-mediated metabolism, into inactive or less active metabolites.
High Plasma Protein Binding: Approximately 90–95% of circulating mebendazole is bound to plasma proteins, leaving only a small unbound fraction to penetrate extraintestinal solid tumors and cross physiological barriers.
2. Crystalline Solid-State Engineering (Polymorph Selection)
Mebendazole exists in three distinct crystalline solid-state forms—polymorphs A, B, and C—which display dramatically different solubility, toxicity, and systemic exposures:
Polymorph A: Possesses minimal intestinal absorption and extremely poor systemic exposure (achieving only 19% of polymorph C’s plasma AUC), rendering it therapeutically ineffective in brain and solid tumor models.
Polymorph B: Demonstrates high systemic absorption (165% of polymorph C’s AUC) but exhibits increased systemic toxicity and lower tissue distribution ratios.
Polymorph C: Identified as the optimal clinical candidate for cancer therapy. It balances low systemic toxicity with therapeutically effective plasma and tissue levels, achieving a peak brain concentration of 7.1 µM and a brain-to-plasma AUC ratio of 0.82.
Storage Consideration: Formulations utilizing polymorph C must be stored under controlled conditions, as exposure to elevated temperature and humidity causes polymorph C to degrade over time into the inactive polymorph A.
3. Dietary Lipids & Co-Administration Strategies
High-Fat Meals: Co-administering mebendazole with fatty foods or high-fat meals increases gastrointestinal absorption up to 5-fold in humans and animals, raising peak plasma concentrations from ~17 nmol/L in fasting to 91–142 nmol/L.
Lipid Suspensions: In preclinical animal studies, researchers routinely suspend mebendazole powder or ground tablets in lipid vehicles—such as 50% sesame oil, oleic acid, or soybean oil—to optimize intestinal absorption and maintain therapeutic plasma levels.
4. Pharmacokinetic & Transporter Modulation
Efflux Transporter Blockade (P-gp / BCRP): Co-administering mebendazole polymorph C with elacridar, a potent inhibitor of P-glycoprotein (P-gp / ABCB1) and breast cancer resistance protein (BCRP), increases its brain-to-plasma distribution ratio (from 0.75 to 1.03) and significantly extends median survival in intracranial glioma and medulloblastoma models.
CYP450 Enzyme Inhibition: Concurrent administration with the H2-receptor antagonist cimetidine inhibits hepatic first-pass cytochrome P450 enzymes, elevating peak mebendazole serum levels (Cmax) from ~55.7 ng/mL to 82.3 ng/mL (~0.28 µM) during chronic dosing.
5. Advanced Micro- and Nano-Formulation Technologies
L-HPC Redispersible Microparticles (RDM): Formulating mebendazole into redispersible microparticles with low-substituted hydroxypropylcellulose (L-HPC) at 1:2.5 or 1:5 ratios converts crystalline mebendazole into an amorphous phase with enhanced wettability and rapid dissolution. In vivo, L-HPC RDM formulations yield a 2.67- to 2.97-fold increase in oral AUC and a 4.35- to 6.23-fold increase in Cmax compared to pure mebendazole, achieving potent therapeutic efficacy at low doses (5 mg/kg).
Novel Delivery Systems: Active development includes nanocarrier strategies such as cyclodextrin inclusion complexes, solid dispersions, polymeric micelles, liposomes, and solid lipid nanoparticles, designed to prevent drug re-aggregation and sustain systemic circulation for targeted cancer delivery.
de la Torre-Iglesias, P. M., García-Rodriguez, J. J., Torrado, G., Torrado, S., Torrado-Santiago, S., & Bolás-Fernández, F. (2014). Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose. Drug Design, Development and Therapy, 8, 1467–1479.